Correlation between KIT expression and KIT mutation in melanoma: A study of 173 cases with emphasis on the acral-lentiginous/mucosal type

Modern Pathology

Volumn 22, Issue 11, 2009, Pages 1446-1456

  Torres Cabala, Carlos A ^a,b   Wang, Wei Lien ^a   Trent, Jonathan ^a   Yang, Dan ^a   Chen, Su ^a   Galbincea, John ^a   Kim, Kevin B ^a   Woodman, Scott ^a   Davies, Michael ^a   Plaza, Jose A ^a   Nash, J W ^a   Prieto, Victor G ^a,b   Lazar, Alexander J ^a,b   Ivan, Doina ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acral lentiginous; Immunohistochemistry; KIT; Melanoma; Mucosal; Mutation

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIT GENE; MAJOR CLINICAL STUDY; MALE; MALIGNANT LENTIGO; MELANOMA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-KIT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SKIN; SKIN NEOPLASMS;

EID: 70350668375     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.116     Document Type: Article

References (53)

1. Grichnik JM, Burch JA, Burchette J, et al. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1998;111:233-238
2. Grichnik JM. Kit and melanocyte migration. J Invest Dermatol 2006;126:945-947
3. Holden JA, Willmore-Payne C, Layfield LJ. Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology. Exp Mol Pathol 2008;85:68-75
4. Alexeev V, Yoon K. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 2006;126:1102-1110
5. Natali PG, Nicotra MR, Winkler AB, et al. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 1992;52:197-201
6. Montone KT, van Belle P, Elenitsas R, et al. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 1997;10:939-944
7. Guerriere-Kovach PM, Hunt EL, Patterson JW, et al. Primary melanoma of the skin and cutaneous melano-matous metastases: comparative histologic features and immunophenotypes. Am J Clin Pathol 2004;122: 70-77
8. Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004; 22:4514-4522
9. Willmore-Payne C, Holden JA, Tripp S, et al. Human malignant melanoma: detection of BRAF-and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 2005;36:486-493
10. Fiorentini G, Rossi S, Lanzanova G, et al. Potential use of imatinib mesylate in ocular melanoma and lipo-sarcoma expressing immunohistochemical c-KIT (CD117). Ann Oncol 2003;14:805
11. Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008;99:734-740
12. Quintas-Cardama A, Lazar AJ, Woodman SE, et al. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 2008;5:737-740
13. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008;26:2046-2051
14. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008;14:2717-2725
15. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008;21:492-493
16. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-4346
17. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14:6821-6828
18. Antonescu CR, Busam KJ, Francone TD, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007;121: 257-264
19. Jiang X, Zhou J, Yuen NK, et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008;14:7726-7732
20. Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004;64:5913-5919
21. Lassam N, Bickford S. Loss of c-kit expression in cultured melanoma cells. Oncogene 1992;7:51-56
22. Funasaka Y, Boulton T, Cobb M, et al. c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Mol Biol Cell 1992;3:197-209
23. Shen SS, Zhang PS, Eton O, et al. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 2003;30:539-547
24. Potti A, Hille RC, Koch M. Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications. J Carcinog 2003;2:8
25. Chute DJ, Cousar JB, Mills SE. Anorectal malignant melanoma: morphologic and immunohistochemical features. Am J Clin Pathol 2006;126:93-100
26. Zyrek-Betts J, Micale M, Lineen A, et al. Malignant blue nevus with lymph node metastases. J Cutan Pathol 2008;35:651-657
27. Alexis JB, Martinez AE, Lutzky J. An immunohisto-chemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Res 2005;15:283-285
28. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002; 117:188-193
29. Zakut R, Perlis R, Eliyahu S, et al. KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene 1993;8: 2221-2229
30. Huang S, Jean D, Luca M, et al. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J 1998;17: 4358-4369 (Pubitemid 28362626)
31. Eckhart L, Bach J, Ban J, et al. Melanin binds reversibly to thermostable DNA polymerase and inhibits its activity. Biochem Biophys Res Commun 2000;271: 726-730
32. Giambernardi TA, Rodeck U, Klebe RJ. Bovine serum albumin reverses inhibition of RT-PCR by melanin. Biotechniques 1998;25:564-566
33. Rivera RS, Nagatsuka H, Gunduz M, et al. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 2008;452:27-32
34. Haller F, Gunawan B, von Heydebreck A, et al. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. Clin Cancer Res 2005;11:6589-6597
35. Lasota J, Jasinski M, Sarlomo-Rikala M, et al. Mutations in exon 11 of c-Kit occur preferentially in malignant vs benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999;154:53-60
36. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-1103
37. McAuliffe JC, Wang WL, Pavan GM, et al. Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors. Mol Oncol 2008;2:161-163
38. Lasota J, Corless CL, Heinrich MC, et al. Clinicopatho-logic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol 2008; 21:476-484
39. Kinoshita K, Hirota S, Isozaki K, et al. Characterization of tyrosine kinase I domain c-kit gene mutation Asn655Lys newly found in primary jejunal gastro-intestinal stromal tumor. Am J Gastroenterol 2007; 102:1134-1136
40. Desai J, Shankar S, Heinrich MC, et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 2007;13:5398-5405
41. Beghini A, Cairoli R, Morra E, et al. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. Blood Cells Mol Dis 1998;24: 262-270
42. Verzijl A, Heide R, Oranje AP, et al. C-kit Asp-816-Val mutation analysis in patients with mastocytosis. Dermatology 2007;214:15-20
43. Frost MJ, Ferrao PT, Hughes TP, et al. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1:1115-1124
44. Tian Q, Frierson Jr HF, Krystal GW, et al. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999;154:1643-1647
45. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastro-enterology 2005;128:270-279
46. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182-4190
47. Bastian BC, LeBoit PE, Hamm H, et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998;58:2170-2175
48. Smalley KS, Contractor R, Nguyen TK, et al. Identification of a novel subgroup of melanomas with KIT/ cyclin-dependent kinase-4 overexpression. Cancer Res 2008;68:5743-5752
49. Lefevre G, Glotin AL, Calipel A, et al. Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem 2004; 279:31769-31779
50. Hofmann UB, Kauczok-Vetter CS, Houben R, et al. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res 2009;15:324-329
51. Wyman K, Atkins MB, Prieto V, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006;106:2005-2011
52. Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005;92:1398-1405
53. Ivan D, Niveiro M, Diwan AH, et al. Analysis of protein tyrosine kinases expression in the melanoma metas-tases of patients treated with Imatinib Mesylate (STI571, Gleevec). J Cutan Pathol 2006;33:280-285